drugset / Trial / NCT01263444
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
Timeline
- Start
- 2011-03
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brinzolamide | Small molecule | 1 % | Topical |
| Subject | Timolol | Other / unclassified | 0.5 % | Topical |
| Background | Bimatoprost | Other / unclassified | — | Topical |
| Background | Latanoprost | Small molecule | — | Topical |
| Background | Tafluprost | Other / unclassified | — | Topical |
| Background | Travoprost | Other / unclassified | — | Topical |